United Therapeutics CORP Form 4 insider transactions

Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 15, 2026.

Paul A Mahon, EVP & GENERAL COUNSEL of UNITED THERAPEUTICS Corp, sold 8,300 shares of common stock on July 16, 2026.

Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 14, 2026.

Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 13, 2026.

Richard Giltner, a Director of UNITED THERAPEUTICS Corp, reported multiple transactions in common stock on July 9, 2026.

Ray Kurzweil, a Director of UNITED THERAPEUTICS Corp, reported multiple transactions in common stock on July 9, 2026.

Nilda Mesa, a Director of UNITED THERAPEUTICS Corp, reported multiple transactions in common stock on July 9, 2026.

Judy D. Olian, a Director of UNITED THERAPEUTICS Corp, reported multiple transactions in common stock on July 9, 2026.

Christopher Patusky, a Director of UNITED THERAPEUTICS Corp, reported multiple transactions in common stock on July 9, 2026.

Louis W Sullivan, a Director of UNITED THERAPEUTICS Corp, reported multiple transactions in common stock on July 9, 2026.

Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 10, 2026.

United Therapeutics Director Jan Malcolm reports transactions involving the acquisition of common stock via restricted stock unit vesting and subsequent sale.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported a transaction involving the acquisition of 9,500 common shares on July 9, 2026, under a 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., executed a series of stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

United Therapeutics Chairperson & CEO Martine A. Rothblatt reported transactions involving the exercise of stock options and the sale of common stock, executed under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported a series of stock transactions on July 2, 2026, involving the exercise of stock options and subsequent sale of common stock.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, reported a series of transactions involving the exercise of stock options and the sale of common stock on June 29, 2026.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the acquisition and disposition of common stock on June 26, 2026, under a Rule 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the acquisition and disposition of common stock on June 25, 2026, under a Rule 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the exercise of stock options and sale of common stock on June 24, 2026, under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported significant stock transactions on June 23, 2026, involving option exercises and stock sales under a 10b5-1 plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving common stock and stock options on June 22, 2026, executed under a 10b5-1 trading plan.

Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp, reported transactions involving the exercise of stock options and sale of common stock.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the sale of common stock acquired through stock option exercises, executed under a pre-arranged 10b5-1 trading plan.

Chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a 10b5-1 plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp. CFO and Treasurer James Edgemond reported the sale of 10,000 shares of common stock, acquired through stock options, as part of a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported a series of transactions involving the exercise of stock options and the sale of common stock on June 12, 2026, executed under a Rule 10b5-1 trading plan.